Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKesson
Merck
Medtronic
Harvard Business School

Last Updated: May 25, 2022

Maraviroc - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for maraviroc and what is the scope of patent protection?

Maraviroc is the generic ingredient in two branded drugs marketed by Viiv Hlthcare and Hetero Labs Ltd Iii, and is included in three NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Maraviroc has ninety-six patent family members in fifty-five countries.

There are two drug master file entries for maraviroc. Two suppliers are listed for this compound.

Summary for maraviroc
International Patents:96
US Patents:2
Tradenames:2
Applicants:2
NDAs:3
Drug Master File Entries: 2
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 82
Clinical Trials: 139
Patent Applications: 6,786
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in maraviroc?maraviroc excipients list
DailyMed Link:maraviroc at DailyMed
Recent Clinical Trials for maraviroc

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Orlando Immunology CenterPhase 4
Centro de Investigación en. Enfermedades Infecciosas, MexicoPhase 2
Hospital General de México Dr. Eduardo LiceagaPhase 2

See all maraviroc clinical trials

Pharmacology for maraviroc
Paragraph IV (Patent) Challenges for MARAVIROC
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SELZENTRY Tablets maraviroc 150 mg and 300 mg 022128 2 2011-08-08

US Patents and Regulatory Information for maraviroc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-002 Aug 6, 2007 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Hetero Labs Ltd Iii MARAVIROC maraviroc TABLET;ORAL 203347-001 Feb 7, 2022 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for maraviroc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-004 Nov 4, 2016 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for maraviroc

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1284974 PA 2008 004, C 1284974 Lithuania See Plans and Pricing PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 20070918
1284974 PA2008004,C1284974 Lithuania See Plans and Pricing PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 0070918
1284974 122008000011 Germany See Plans and Pricing PRODUCT NAME: 4,4-DIFLUORO-N-((1S)-3-((1R,3S,5S)-3-(3-METHYL-5-(PROPAN-2-YL)-4H-1,2,4-TRIAZOL-4-YL)-8-AZABICYCLO(3.2.1)OCTAN-8-YL)-1-PHENYLPROPYL)CYCLOHEXANECARBOXAMIDE; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Colorcon
McKesson
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.